Developer docs
API playgroundTry for free, no card

Search company profiles

Mabion S.A.

Full company profile

uuid000b2ml

Namestring
Mabion S.A.
Legal namestring
Mabion S.A.
Websiteurl
mabion.eu
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) founded in 2007 and headquartered in Konstantynów Łódzki, Poland. The company provides end-to-end biologics development and manufacturing services to biopharmaceutical clients, spanning cell line development, process development, analytical services, drug substance manufacturing, and fill-finish for recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Manufacturing is based on mammalian cell culture using single-use bioreactor technology at 2000L–4000L commercial scale, with a planned upgrade to 8000L, operated across two GMP-certified facilities (a Research & Development Centre and a Research & Production Centre) built in part with over PLN 172M of EU/ERDF co-financing. Mabion is publicly listed on the Warsaw Stock Exchange (ticker: MAB) and serves a global client base across Europe, the Americas, and Brazil, with named customers including Novavax (vaccine manufacturing under a strategic cooperation extended through end-2029), Instituto de Biologia Molecular do Paraná (IBMP), Novalgen, and WPD Pharmaceuticals.

The company monetizes primarily through fee-for-service CDMO contracts and co-development partnerships, complemented by a selective proprietary pipeline of biosimilar and innovative biologic assets — most notably MabionCD20 (reactivated in 2026 for orphan disease indications under existing FDA Orphan Drug Designations for autoimmune hemolytic anemia and membranous nephropathy), plus the historical MabionHER2 and MabionEGFR programs. Its go-to-market model is direct enterprise field sales, supported by a Business Development team and newly appointed regional BD leadership for Europe (Nigel Stapleton) and North America (Marty Henehan); demand generation relies on industry conferences (BIO, CPHI, Bio-Europe, DCAT Week), scientific content marketing through its Science Hub, and direct outreach. Revenue mechanics are project-based and quote-based against enterprise biopharma clients.

Mabion's capital base is a mix of EU grants, public equity, and debt. Major shareholders include Twiti Investments Limited (11.87% of share capital, 14.17% of votes), the Maciej Wieczorek group (7.99% / 10.07%), and Polfarmex S.A. (9.12% / 11.04%), with the remainder widely held. The company secured an EBRD loan of approximately $15M in February 2023, bridge financing from Twiti in October 2025, and Japanese investor CBC Co., Ltd. debt in March 2026. Leadership was substantially refreshed in 2025 with the appointment of Gregor Kawaletz (ex-Catalent, Recipharm, NextPharma, IDT-Biologika, Albumedix) as CEO alongside other CXO hires from Janssen, J&J-Merck, and Biocon, positioning the company to execute on its Strategy 2025-2030 and its stated target of operational break-even by end-2026.

Short descriptiontext

Mabion S.A. is a Polish biopharmaceutical CDMO providing end-to-end biologics services — cell line development, process development, analytics, GMP drug substance, and fill-finish — to global biopharmaceutical clients using single-use mammalian cell culture technology at 2000L–4000L scale.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersKonstantynów, Poland
HQ citystring
Konstantynów
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics CDMO services, contract manufacturing organization, monoclonal antibody production, biosimilars development, GMP drug substance manufacturing
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biologics Contract Development and Manufacturing (CDMO)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Mabion provides fee-for-service CDMO services to biopharmaceutical companies. Services span process development, analytics, drug substance manufacturing, and fill-finish for biologics including biosimilars, antibodies, ADCs, and recombinant proteins. Revenue is generated through project-based contracts with pharmaceutical clients.

mabion.eu
2Co-development Partnerships
TypeLicensing Royalties
Description

Mabion engages in co-development partnerships where it contributes development and manufacturing expertise in exchange for development fees and potential milestone payments or royalties.

mabion.eu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics services spanning cell line development, process development, analytics, drug substance manufacturing, and fill-finish under GMP conditions. The company specializes in mammalian cell culture-based production of recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars, operating two modern facilities (Research & Development Centre and Research & Production Centre) in Konstantynów Łódzki, Poland, with single-use bioreactor capacity at the 2000L–4000L scale. In parallel, Mabion pursues proprietary innovative biologics programs such as MabionCD20 (an anti-CD20 monoclonal antibody with FDA Orphan Drug Designations) and co-development partnerships with biopharmaceutical clients worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First and largest biopharmaceutical plant in the world operating in disposable technology
+2 more records
Product overview1 text field

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) providing end-to-end biologics development and manufacturing services. The company operates two modern facilities—a Research&Development Centre and Research&Production Centre—specializing in sterile biotechnological products manufactured under GMP conditions using mammalian cell cultures. Mabion's service portfolio comprises CDMO Services (covering process development, analytics, and drug substance manufacturing), Co-Development Partnership Models (collaborative approaches replacing traditional contractor relationships), and Innovative Biologics programs including the MabionCD20 orphan drug asset. The company also offers specialized services in cell line development, ADC manufacturing, biosimilars, and clinical trial support through GLP-certified laboratories. Key partnerships include Novavax (vaccine manufacturing), Oddifact (AI-driven orphan drug development for MabionCD20), WPD Pharmaceuticals (ADC development), Celon Pharma (ADC products), and Sartorius (biopharmaceutical development cooperation).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

Mabion and Novavax have extended strategic cooperation for another three years until the end of 2029. Mabion provides contract manufacturing services for COVID-19 vaccine antigen production. The partnership has expanded to include analytical work for a combined influenza and COVID vaccine product. Novavax is a major customer driving significant revenue.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

French TechDev company Oddifact partnered with Mabion to explore MabionCD20 as a treatment for rare diseases using AI platform to identify orphan drug applications. This strategic pivot reopens the CD20 program previously developed as a rituximab biosimilar, now targeting the rare disease space through orphan drug designations.

3KriSan Biotech
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Mabion and KriSan Biotech signed Letter of Intent to explore ADC collaboration. The partnership aims to leverage combined expertise in antibody-drug conjugate development and manufacturing.

mabion.eu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Mabion and WPD Pharmaceuticals strengthened cooperation, planning joint development of innovative ADC molecules. Mabion completed analytical development project for WPD-401, delivering 20 analytical methods. Strategic collaboration in advanced conjugated oncology therapeutics.

5Celon Pharma S.A.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Mabion S.A. and Celon Pharma S.A. plan to initiate collaboration in the development of ADC products. Celon Pharma is also a founding shareholder of Mabion.

mabion.eu
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Mabion and SyVento plan to begin cooperation in aseptic fill and finish of drug products. Partnership to expand service capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Mabion released first batch of Novalgen's next-generation T-cell engager, NVG-222, for first-in-human clinical trials. Demonstrates Mabion's capabilities in manufacturing novel T-cell engager molecules.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-14
Description

Mabion and Sartorius announced strategic cooperation to advance biopharmaceutical development. Partnership includes commercializing services together and collaboration with IBMP on cell culture and process development.

9Instituto de Biologia Molecular do Paraná (IBMP)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-14
Description

Mabion entered master agreement with IBMP for CDMO services in Brazil. Expanded cooperation with new orders under the framework agreement. Partnership supported by Sartorius collaboration.

mabion.eu
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large-scale mammalian CDMO offering process development, drug substance manufacturing, and fill-finish services to global biopharma. Comparable on core biologics CDMO offering, with significantly greater installed bioreactor capacity and global footprint.

TypeEmerging player
Description

Iceland-headquartered biosimilars developer and manufacturer focused on mAb biosimilars with in-house manufacturing capability. Comparable as a competing biosimilars-focused player with proprietary products and CDMO-grade manufacturing capacity.

TypeDirect peer
Description

European-headquartered biologics CDMO focused on mammalian cell culture, offering cell line development through commercial manufacturing. Closely comparable on European footprint, mid-sized scale, and end-to-end service model.

TypeOthers
Description

Global supplier of bioprocessing equipment, single-use technologies, and process solutions for biologics manufacturing. Relevant as both Mabion's strategic technology partner and as a benchmark for the enabling technologies used in Mabion's facility.

TypeDirect peer
Description

Mammalian and microbial CDMO offering cell line development, process development, analytics, and GMP manufacturing for mAbs, recombinant proteins, and complex modalities. Comparable on integrated biologics CDMO model and ability to serve clinical through commercial supply.

TypeBroad incumbent
Description

Global leader in biologics CDMO services with mammalian cell culture manufacturing across multiple sites and large commercial-scale capacity. Directly comparable as a mammalian-cell-culture CDMO serving biopharma clients, though at materially larger scale and broader service portfolio.

TypeBroad incumbent
Description

End-to-end biologics CDMO providing cell line development, process development, and GMP manufacturing across multiple sites. Directly comparable end-to-end service model for mAbs and recombinant proteins, with substantially larger global scale.

TypeDirect peer
Description

European biologics CDMO and biosimilars developer offering mammalian cell culture development and manufacturing services. Comparable on biosimilars positioning, mammalian manufacturing capability, and mid-sized European CDMO profile.

9Celon Pharma S.A.
TypeOthers
Description

Polish pharmaceutical company and founding shareholder of Mabion, now collaborating on ADC development. Comparable as a domestic Polish pharma partner and as an adjacent biologics developer, with a partial overlap on oncology pipeline ambitions.

TypeDirect peer
Description

Polish-headquartered biologics CDMO and biosimilars developer with mammalian cell culture capabilities. Most direct European regional peer given shared Polish origin, focus on biosimilars, and biologics manufacturing service model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mabion S.A.

Biologics Contract Development and Manufacturing (CDMO)mabion.eu

Mabion S.A. is a Polish biopharmaceutical CDMO providing end-to-end biologics services — cell line development, process development, analytics, GMP drug substance, and fill-finish — to global biopharmaceutical clients using single-use mammalian cell culture technology at 2000L–4000L scale.

What Mabion S.A. does

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) founded in 2007 and headquartered in Konstantynów Łódzki, Poland. The company provides end-to-end biologics development and manufacturing services to biopharmaceutical clients, spanning cell line development, process development, analytical services, drug substance manufacturing, and fill-finish for recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Manufacturing is based on mammalian cell culture using single-use bioreactor technology at 2000L–4000L commercial scale, with a planned upgrade to 8000L, operated across two GMP-certified facilities (a Research & Development Centre and a Research & Production Centre) built in part with over PLN 172M of EU/ERDF co-financing. Mabion is publicly listed on the Warsaw Stock Exchange (ticker: MAB) and serves a global client base across Europe, the Americas, and Brazil, with named customers including Novavax (vaccine manufacturing under a strategic cooperation extended through end-2029), Instituto de Biologia Molecular do Paraná (IBMP), Novalgen, and WPD Pharmaceuticals.

The company monetizes primarily through fee-for-service CDMO contracts and co-development partnerships, complemented by a selective proprietary pipeline of biosimilar and innovative biologic assets — most notably MabionCD20 (reactivated in 2026 for orphan disease indications under existing FDA Orphan Drug Designations for autoimmune hemolytic anemia and membranous nephropathy), plus the historical MabionHER2 and MabionEGFR programs. Its go-to-market model is direct enterprise field sales, supported by a Business Development team and newly appointed regional BD leadership for Europe (Nigel Stapleton) and North America (Marty Henehan); demand generation relies on industry conferences (BIO, CPHI, Bio-Europe, DCAT Week), scientific content marketing through its Science Hub, and direct outreach. Revenue mechanics are project-based and quote-based against enterprise biopharma clients.

Mabion's capital base is a mix of EU grants, public equity, and debt. Major shareholders include Twiti Investments Limited (11.87% of share capital, 14.17% of votes), the Maciej Wieczorek group (7.99% / 10.07%), and Polfarmex S.A. (9.12% / 11.04%), with the remainder widely held. The company secured an EBRD loan of approximately $15M in February 2023, bridge financing from Twiti in October 2025, and Japanese investor CBC Co., Ltd. debt in March 2026. Leadership was substantially refreshed in 2025 with the appointment of Gregor Kawaletz (ex-Catalent, Recipharm, NextPharma, IDT-Biologika, Albumedix) as CEO alongside other CXO hires from Janssen, J&J-Merck, and Biocon, positioning the company to execute on its Strategy 2025-2030 and its stated target of operational break-even by end-2026.

Mabion S.A. firmographics

Firmographics
Name
Mabion S.A.
Legal name
Mabion S.A.
Website
https://mabion.eu
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Mabion S.A. is a Polish biopharmaceutical CDMO providing end-to-end biologics services — cell line development, process development, analytics, GMP drug substance, and fill-finish — to global biopharmaceutical clients using single-use mammalian cell culture technology at 2000L–4000L scale.
Ownership category
akta.pro rank

Mabion S.A. industry classification

Industry
Product category
Biologics Contract Development and Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Biologics CDMO services
  • Contract manufacturing organization
  • Monoclonal antibody production
  • Biosimilars development
  • GMP drug substance manufacturing

Where Mabion S.A. is headquartered

Location

Headquarters

HQ city
Konstantynów
HQ country
Poland
HQ region
Europe

Offices1 record

Markets served

Mabion S.A. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Mabion provides fee-for-service CDMO services to biopharmaceutical companies. Services span process development, analytics, drug substance manufacturing, and fill-finish for biologics including biosimilars, antibodies, ADCs, and recombinant proteins. Revenue is generated through project-based contracts with pharmaceutical clients.
  2. Co-development Partnerships: Mabion engages in co-development partnerships where it contributes development and manufacturing expertise in exchange for development fees and potential milestone payments or royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Mabion S.A. product offering

Product offering

Core offering

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics services spanning cell line development, process development, analytics, drug substance manufacturing, and fill-finish under GMP conditions. The company specializes in mammalian cell culture-based production of recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars, operating two modern facilities (Research & Development Centre and Research & Production Centre) in Konstantynów Łódzki, Poland, with single-use bioreactor capacity at the 2000L–4000L scale. In parallel, Mabion pursues proprietary innovative biologics programs such as MabionCD20 (an anti-CD20 monoclonal antibody with FDA Orphan Drug Designations) and co-development partnerships with biopharmaceutical clients worldwide.

Product overview

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) providing end-to-end biologics development and manufacturing services. The company operates two modern facilities—a Research&Development Centre and Research&Production Centre—specializing in sterile biotechnological products manufactured under GMP conditions using mammalian cell cultures. Mabion's service portfolio comprises CDMO Services (covering process development, analytics, and drug substance manufacturing), Co-Development Partnership Models (collaborative approaches replacing traditional contractor relationships), and Innovative Biologics programs including the MabionCD20 orphan drug asset. The company also offers specialized services in cell line development, ADC manufacturing, biosimilars, and clinical trial support through GLP-certified laboratories. Key partnerships include Novavax (vaccine manufacturing), Oddifact (AI-driven orphan drug development for MabionCD20), WPD Pharmaceuticals (ADC development), Celon Pharma (ADC products), and Sartorius (biopharmaceutical development cooperation).

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • First and largest biopharmaceutical plant in the world operating in disposable technology
  • +2 more outcomes

Companies that use Mabion S.A.

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Mabion S.A. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mabion S.A. partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Novavax, Inc.coreStrategic or Co-development Partner · 18 June 2026Mabion and Novavax have extended strategic cooperation for another three years until the end of 2029. Mabion provides contract manufacturing services for COVID-19 vaccine antigen production. The partnership has expanded to include analytical work for a combined influenza and COVID vaccine product. Novavax is a major customer driving significant revenue.
  • Oddifact SAScoreStrategic or Co-development Partner · 17 June 2026French TechDev company Oddifact partnered with Mabion to explore MabionCD20 as a treatment for rare diseases using AI platform to identify orphan drug applications. This strategic pivot reopens the CD20 program previously developed as a rituximab biosimilar, now targeting the rare disease space through orphan drug designations.
  • KriSan BiotechminorStrategic or Co-development Partner · 1 June 2026Mabion and KriSan Biotech signed Letter of Intent to explore ADC collaboration. The partnership aims to leverage combined expertise in antibody-drug conjugate development and manufacturing.
  • WPD PharmaceuticalscoreStrategic or Co-development Partner · 12 March 2026Mabion and WPD Pharmaceuticals strengthened cooperation, planning joint development of innovative ADC molecules. Mabion completed analytical development project for WPD-401, delivering 20 analytical methods. Strategic collaboration in advanced conjugated oncology therapeutics.
  • Celon Pharma S.A.minorStrategic or Co-development Partner · 13 January 2026Mabion S.A. and Celon Pharma S.A. plan to initiate collaboration in the development of ADC products. Celon Pharma is also a founding shareholder of Mabion.
  • SyVentominorStrategic or Co-development Partner · 15 December 2025Mabion and SyVento plan to begin cooperation in aseptic fill and finish of drug products. Partnership to expand service capabilities.
  • NovalgencoreStrategic or Co-development Partner · 17 June 2025Mabion released first batch of Novalgen's next-generation T-cell engager, NVG-222, for first-in-human clinical trials. Demonstrates Mabion's capabilities in manufacturing novel T-cell engager molecules.
  • Sartorius Stedim Cellca GmbHcoreTechnology or Integration · 14 April 2025Mabion and Sartorius announced strategic cooperation to advance biopharmaceutical development. Partnership includes commercializing services together and collaboration with IBMP on cell culture and process development.
  • Instituto de Biologia Molecular do Paraná (IBMP)coreStrategic or Co-development Partner · 14 April 2025Mabion entered master agreement with IBMP for CDMO services in Brazil. Expanded cooperation with new orders under the framework agreement. Partnership supported by Sartorius collaboration.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Mabion S.A. competitors and assessment

Company assessment

Broad incumbents

  • Samsung Biologics: Large-scale mammalian CDMO offering process development, drug substance manufacturing, and fill-finish services to global biopharma. Comparable on core biologics CDMO offering, with significantly greater installed bioreactor capacity and global footprint.
  • Lonza Group AG: Global leader in biologics CDMO services with mammalian cell culture manufacturing across multiple sites and large commercial-scale capacity. Directly comparable as a mammalian-cell-culture CDMO serving biopharma clients, though at materially larger scale and broader service portfolio.
  • WuXi Biologics: End-to-end biologics CDMO providing cell line development, process development, and GMP manufacturing across multiple sites. Directly comparable end-to-end service model for mAbs and recombinant proteins, with substantially larger global scale.

Emerging players

  • Alvotech: Iceland-headquartered biosimilars developer and manufacturer focused on mAb biosimilars with in-house manufacturing capability. Comparable as a competing biosimilars-focused player with proprietary products and CDMO-grade manufacturing capacity.

Direct peers

  • Rentschler Biopharma: European-headquartered biologics CDMO focused on mammalian cell culture, offering cell line development through commercial manufacturing. Closely comparable on European footprint, mid-sized scale, and end-to-end service model.
  • AGC Biologics: Mammalian and microbial CDMO offering cell line development, process development, analytics, and GMP manufacturing for mAbs, recombinant proteins, and complex modalities. Comparable on integrated biologics CDMO model and ability to serve clinical through commercial supply.
  • mAbxience: European biologics CDMO and biosimilars developer offering mammalian cell culture development and manufacturing services. Comparable on biosimilars positioning, mammalian manufacturing capability, and mid-sized European CDMO profile.
  • Polpharma Biologics: Polish-headquartered biologics CDMO and biosimilars developer with mammalian cell culture capabilities. Most direct European regional peer given shared Polish origin, focus on biosimilars, and biologics manufacturing service model.

Others

  • Sartorius AG: Global supplier of bioprocessing equipment, single-use technologies, and process solutions for biologics manufacturing. Relevant as both Mabion's strategic technology partner and as a benchmark for the enabling technologies used in Mabion's facility.
  • Celon Pharma S.A. Polish pharmaceutical company and founding shareholder of Mabion, now collaborating on ADC development. Comparable as a domestic Polish pharma partner and as an adjacent biologics developer, with a partial overlap on oncology pipeline ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Mabion S.A. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mabion S.A. leadership team

Management profile

Number of profiles

Profiles15 records

Mabion S.A. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mabion S.A. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabion S.A.

What does Mabion S.A. do?

Mabion S.A. is a Polish biotechnology company and Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics services spanning cell line development, process development, analytics, drug substance manufacturing, and fill-finish under GMP conditions. The company specializes in mammalian cell culture-based production of recombinant proteins, monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars, operating two modern facilities (Research & Development Centre and Research & Production Centre) in Konstantynów Łódzki, Poland, with single-use bioreactor capacity at the 2000L–4000L scale. In parallel, Mabion pursues proprietary innovative biologics programs such as MabionCD20 (an anti-CD20 monoclonal antibody with FDA Orphan Drug Designations) and co-development partnerships with biopharmaceutical clients worldwide.

Is Mabion S.A. a public or private company?

Mabion S.A. is a public company. It is classified as public and is currently operating.

When was Mabion S.A. founded?

Mabion S.A. was founded in 2007. It employs 101 to 250 people.

Where is Mabion S.A. based?

Mabion S.A. is headquartered in Konstantynów, Poland, in the Europe region.

How does Mabion S.A. make money?

Two revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are co-development Partnerships.

Who are Mabion S.A.'s main competitors?

Broad incumbents on record are Samsung Biologics, Lonza Group AG and WuXi Biologics. Alvotech is listed as an emerging player. Direct peers are Rentschler Biopharma, AGC Biologics, mAbxience and Polpharma Biologics. Others are Sartorius AG and Celon Pharma S.A..

Does Mabion S.A. have an API?

No public API is recorded for Mabion S.A..

What industry is Mabion S.A. in?

Mabion S.A.'s product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAAAHAA, Monoclonal Antibody (mAb) Biosimilars. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageOddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune ThrombocytopeniaOddifact SAS and Mabion S.A. announced on August 26, 2026 that the FDA granted a Type B pre-IND meeting for RTX-NP (MabionCD20), a rituximab product for adult patients with persistent or chronic primary immune thrombocytopenia. The FDA opened Pre-IND file PIND 183961 under Oddifact's name, engaging the Division of Nonmalignant Hematology. The companies plan to use the meeting to align on development questions before BLA submission.MabionThe New Era of Biosimilar DevelopmentRegulators including the European Medicines Agency (EMA), FDA, and Health Canada are shifting towards streamlined biosimilar development pathways that may waive costly Phase III efficacy trials. This regulatory change is projected to reduce development costs by up to 50% and shorten time-to-market by several years, significantly lowering barriers for smaller biotech companies. Industry players like Mabion and Formycon are adapting their strategies and services to align with these new scientific and economic standards.MabionSterile Fill and Finish for Biologics Drug ProductMabion is promoting its comprehensive sterile fill and finish services for biologics drug products, which include vial sterilization, filling, packaging, serialization, and quality testing. The company highlights its use of automated aseptic filling lines with isolator technology capable of processing up to 6,000 vials per hour while ensuring compliance with global regulatory standards.MabionTime to Market Strategy – 5 CDMO Tactics to Speed Up Biologic LaunchesThis article describes how Contract Development and Manufacturing Organizations (CDMOs) help biotech companies accelerate biologic drug development through five key tactics: integrated end-to-end services, platform processes, advanced analytics, single-use technologies, and early-phase manufacturing readiness. Mabion, the authoring CDMO, reports that its platform-based approach reduced first GMP batch release time by 40% and production setup time by over 30%, enabling clients to move to clinical manufacturing months ahead of projections. The article emphasizes that being first-to-market offers biologics significant advantages including market exclusivity, physician preference, and early reimbursement traction, with examples showing first-to-market drugs generating billions in annual revenue.YahooShares in Poland's Mabion surge on Novavax vaccine programme dealMabion shares rose over 60% after announcing a framework deal with Novavax for COVID-19 vaccine technology transfer. The agreement aims to complete technology transfer by mid-2021, potentially integrating Mabion's facility into Novavax's commercial supply chain.